WO2001036625A3 - ANTISENSE OLIGONUCLEOTIDE SEQUENCES DERIVED FROM groEL AND groES AS INHIBITORS MICROORGANISMS - Google Patents

ANTISENSE OLIGONUCLEOTIDE SEQUENCES DERIVED FROM groEL AND groES AS INHIBITORS MICROORGANISMS Download PDF

Info

Publication number
WO2001036625A3
WO2001036625A3 PCT/CA2000/001347 CA0001347W WO0136625A3 WO 2001036625 A3 WO2001036625 A3 WO 2001036625A3 CA 0001347 W CA0001347 W CA 0001347W WO 0136625 A3 WO0136625 A3 WO 0136625A3
Authority
WO
WIPO (PCT)
Prior art keywords
microorganisms
groel
groes
inhibitors
antisense oligonucleotide
Prior art date
Application number
PCT/CA2000/001347
Other languages
French (fr)
Other versions
WO2001036625A2 (en
Inventor
Jim A Wright
Aiping H Young
Dominique Dugourd
Original Assignee
Genesense Technologies Inc
Jim A Wright
Aiping H Young
Dominique Dugourd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesense Technologies Inc, Jim A Wright, Aiping H Young, Dominique Dugourd filed Critical Genesense Technologies Inc
Priority to EP00975717A priority Critical patent/EP1246912A2/en
Priority to AU13758/01A priority patent/AU1375801A/en
Priority to CA002392094A priority patent/CA2392094A1/en
Publication of WO2001036625A2 publication Critical patent/WO2001036625A2/en
Publication of WO2001036625A3 publication Critical patent/WO2001036625A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides antisense oligonucleotides which modulate the expression of the groEL or groES genes in microorganisms. This invention is also related to methods of using such oligonucleotides in inhibiting the growth of microorganisms. These antisense oligonucleotides are particularly useful in treating pathological conditions in mammals which are mediated by the growth of microorganisms.
PCT/CA2000/001347 1999-11-18 2000-11-20 ANTISENSE OLIGONUCLEOTIDE SEQUENCES DERIVED FROM groEL AND groES AS INHIBITORS MICROORGANISMS WO2001036625A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00975717A EP1246912A2 (en) 1999-11-18 2000-11-20 Antisense oligonucleotide sequences derived from groel and groes as inhibitors of microorganisms
AU13758/01A AU1375801A (en) 1999-11-18 2000-11-20 Antisense oligonucleotide sequences derived from groEL and groES as inhibitors of microorganisms
CA002392094A CA2392094A1 (en) 1999-11-18 2000-11-20 Antisense oligonucleotide sequences derived from groel and groes as inhibitors of microorganisms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16624999P 1999-11-18 1999-11-18
US60/166,249 1999-11-18

Publications (2)

Publication Number Publication Date
WO2001036625A2 WO2001036625A2 (en) 2001-05-25
WO2001036625A3 true WO2001036625A3 (en) 2002-01-10

Family

ID=22602470

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001347 WO2001036625A2 (en) 1999-11-18 2000-11-20 ANTISENSE OLIGONUCLEOTIDE SEQUENCES DERIVED FROM groEL AND groES AS INHIBITORS MICROORGANISMS

Country Status (5)

Country Link
EP (1) EP1246912A2 (en)
AR (1) AR026550A1 (en)
AU (1) AU1375801A (en)
CA (1) CA2392094A1 (en)
WO (1) WO2001036625A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10048091A1 (en) * 2000-09-28 2002-04-25 Ernst Bayer Use of chemically modified oligodeoxyribonucleotides to suppress the proliferation of human pancreatic tumors
US7101995B2 (en) * 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003533A1 (en) * 1996-07-24 1998-01-29 Oligos Etc. And Oligos Therapeutics, Inc. Antisense oligonucleotides as antibacterial agents
US5945290A (en) * 1998-09-18 1999-08-31 Isis Pharmaceuticals, Inc. Antisense modulation of RhoA expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003533A1 (en) * 1996-07-24 1998-01-29 Oligos Etc. And Oligos Therapeutics, Inc. Antisense oligonucleotides as antibacterial agents
US5945290A (en) * 1998-09-18 1999-08-31 Isis Pharmaceuticals, Inc. Antisense modulation of RhoA expression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEMMINGSEN, S.M. ET AL.: "Homologous plant and bacterial proteins chaperone oligomeric protein assembly", NATURE, vol. 333, no. 6171, 26 May 1988 (1988-05-26), pages 330 - 334, XP002114158 *
IVIC, A. ET AL.: "Deletion of Escherichia coli groEL is complemented by a Rhizobium leguminosarum groEL homologue at 37ŸC but not at 43ŸC", GENE, vol. 194, no. 1, 18 July 1997 (1997-07-18), pages 1 - 8, XP004084653 *

Also Published As

Publication number Publication date
AR026550A1 (en) 2003-02-19
AU1375801A (en) 2001-05-30
CA2392094A1 (en) 2001-05-25
WO2001036625A2 (en) 2001-05-25
EP1246912A2 (en) 2002-10-09

Similar Documents

Publication Publication Date Title
WO1999002673A3 (en) Antisense oligonucleotide sequences as inhibitors of microorganisms
EP1165594A4 (en) Antisense oligonucleotide modulation of stat3 expression
MY162210A (en) Pharmaceutical composition
NO983716D0 (en) Methoxy ethoxy oligonucleotides for modulating protein kinase C expression
WO2005089287A3 (en) Methods and compositions for the specific inhibition of gene expression by double-stranded rna
BR0107536A (en) Isolated rna, soluble extract, method for producing rna from about 21 to about 23 nucleotides in length; isolated dna
WO2001048183A3 (en) Improvements relating to double-stranded rna inhibition
EP0939621A4 (en) Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
EP1537227A4 (en) Method for efficient rna interference in mammalian cells
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
DK1053313T3 (en) Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
WO2003048315A3 (en) Antisense modulation of mdm2 expression
WO1998000532A3 (en) Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
EP0784630A4 (en) Selective inhibition of internally initiated rna translation
WO2004001013A3 (en) Inhibition of gene expression in vertebrates using double-stranded rna (rnai)
WO2003101386A3 (en) Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
WO2009027978A8 (en) NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
WO2001036625A3 (en) ANTISENSE OLIGONUCLEOTIDE SEQUENCES DERIVED FROM groEL AND groES AS INHIBITORS MICROORGANISMS
WO2005045040A3 (en) RNA INTERFERANCE MEDIATED INHIBITION OF CHOLINERGIC MUSCARINIC RECEPTOR (CHRM3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID /siNA)
WO2006066154A3 (en) Casein kinase 2 antisense therapy
WO2002008386A3 (en) Materials and methods for the enhancement of effective root nodulation in legumes
EP1322658A4 (en) Oligonucleotide modulation of her-1 expression
WO2001061030A3 (en) LIBRARIES OF OPTIMUM SUBSEQUENCE REGIONS OF mRNA AND GENOMIC DNA FOR CONTROL OF GENE EXPRESSION
EP1697498A4 (en) Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
EP1584681A3 (en) Antisense oligonucleotide sequences as inhibitors of microorganisms

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2392094

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000975717

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000975717

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000975717

Country of ref document: EP